Key Highlights
- PFSA is trading up 30.72% at $1.1101 on October 22, with a market capitalization of about $0.67 million, calculated.
- The prior close was $0.8492, after an October 15 decline of 16.41% on the day the ISO 13485 certificate was announced.
- Cash was $719,000 at June 30, and the second-quarter net loss was $8.8 million.
- A 1-for-25 reverse split took effect in July and a 1-for-4 split in August.
- The G3 Vision Labs option covers a group with estimated 2025 net revenues of about $111 million.
Why Is Profusa Penny Stock Soaring on October 22?
Profusa (NASDAQ:PFSA) is trading up 30.72% at $1.1101 on October 22, and no company announcement was identified for the session. The prior close was $0.8492, and the company's latest release was the October 15 announcement that it had received an ISO 13485:2016 certificate for its Lumee Oxygen Platform.
That release is context and not today's driver. The stock fell 16.41% on October 15 after rising 47.8% on September 24, when a notified body gave a positive decision on the certification. Moves of this size in either direction have been the pattern for a company with about 605,650 shares outstanding and a market capitalization near $0.67 million, calculated.
Does the ISO Certificate Bring the Lumee Platform Closer to CE Marking?
Profusa develops tissue-integrated biosensors, and the Lumee Oxygen Platform is its lead product. The ISO 13485 certificate covers design, development and manufacture of the biosensors and readers at its Berkeley, California facility and allows the company to begin manufacturing.
It is not CE marking. The company has said the remaining European medical device regulation conformity assessments are still under way, and the outcome and timing of CE marking remain uncertain.
How Severe Are the Cash and Dilution Pressures?
Second-quarter results on August 20 showed cash of $719,000 at June 30, total assets of $1.0 million and liabilities of $28.2 million. The net loss was $8.8 million for the quarter and $12.2 million for the first half. Holders of debt and other liabilities signed $10.7 million of convertible exchange agreements, about $4.57 million of which was exchanged into Series A convertible preferred stock, and the company borrowed $650,000 for working capital.
A 1-for-25 reverse split took effect in July, cutting shares outstanding from about 13.2 million to about 530,000. A 1-for-4 split followed in August, leaving about 605,726 shares. On September 15 the company received a Nasdaq determination confirming compliance with the bid price and equity rules, and it remains under a one-year mandatory panel monitor.
What Does the G3 Vision Labs Option Add to the Outlook?
On July 31 the company signed an option to acquire G3 Vision Labs and its subsidiaries, Med Screen Laboratories, Dominion Diagnostics and Acutis Diagnostics. G3's 2025 net revenues are estimated at about $111 million, based on unaudited management information. The option can be exercised after G3 delivers specified financial information, and conditions include at least $30 million of financings or refinancings and required stockholder approvals.
The key items ahead are the remaining conformity assessments for CE marking, progress on the G3 conditions and further balance sheet actions. No company announcement explains today's move.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...